Kiora Pharmaceuticals has entered into a licensing agreement for KIO-301 with Chong Kun Dang Pharmaceutical Corporation, securing an upfront payment of $1 million. This move expands Kiora's development network in ophthalmology, particularly for retinitis pigmentosa in South Korea.
Key Highlights
- Kiora Pharmaceuticals granted CKD exclusive rights to develop KIO-301 in South Korea.
- The agreement includes a $1 million upfront payment and potential future milestone payments.
- More than 10,000 individuals in South Korea are affected by retinitis pigmentosa.
Kiora Pharmaceuticals has finalized a licensing agreement with Chong Kun Dang Pharmaceutical Corporation (CKD), granting exclusive rights to commercialize its KIO-301 product in South Korea. The deal includes an immediate payment of $1 million and positions Kiora to tap into a significant market for retinitis pigmentosa, a rare genetic condition impacting thousands in the region. This strategic Partnership allows Kiora to enhance its development reach and brings essential resources into play for its ophthalmic drug pipeline.
$1M Upfront Payment Secured
Under the terms of the agreement, CKD will pay Kiora Pharmaceuticals an upfront fee of $1 million. In addition to this initial payment, Kiora will also be entitled to development and regulatory milestone payments contingent upon achieving specific goals. This agreement highlights Kiora's strategy to Leverage its intellectual property related to KIO-301, a molecular photoswitch aimed at treating retinal diseases caused by photoreceptor degeneration.
This innovative approach not only promises a new therapy for individuals suffering from retinitis pigmentosa but also positions Kiora for financial success through ongoing royalties on net sales in South Korea.
CKD Takes Charge of Development
CKD will oversee all development and commercialization efforts for KIO-301 in South Korea. This includes regulatory approval processes and the conduct of Clinical Trials specific to this region. Kiora has indicated that it anticipates efficient coordination among its partners, including Laboratoires Théa, Senju Pharmaceutical, and now CKD, to conduct a combined Phase 3 clinical trial aimed at evaluating the efficacy of KIO-301 in treating retinitis pigmentosa.
The collaborative effort underscores Kiora's commitment to bringing this important treatment to market while capitalizing on CKD's established capabilities in the South Korean pharmaceutical environment.
Eyeing Future Milestones
The agreement comes at a key time as Kiora aims to expand its network in major global markets. By partnering with CKD, Kiora is not only enhancing its strategic interests in South Korea but also aligning with a company that brings both clinical and commercial expertise to the table. CKD's president, Young-Joo Kim, highlighted the urgent need for effective treatments for retinitis pigmentosa, noting that there are currently limited Options available.
With more than 10,000 patients in South Korea affected by this condition, the deal could significantly impact patient care and Kiora's Revenue streams moving forward.
Next Steps for Investors
Kiora Pharmaceuticals announced the licensing agreement on August 19, 2026, with the effective date set for August 20, 2026. Moving ahead, Kiora will focus on supporting CKD in the development and regulatory submissions for KIO-301 while also channeling resources toward evaluating its other product, KIO-104. Investors are keenly watching for further updates regarding the progress of KIO-301 in clinical trials and any developments related to Kiora's pipeline expansion.
Future announcements may include insights into milestone payments and the anticipated outcomes of the Phase 3 clinical trials.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...